PubMed HealthSearch

PubMed · 42693268

How contemporary academic structures constrain scientific creativity and hold back early-career researchers.

Abstract

We argue that contemporary scientific systems progressively constrain high-risk and conceptually innovative research while being increasingly structured around short funding cycles, productivity-based evaluation criteria and risk-averse frameworks that favour predictable and non-transformative research outputs. Drawing on recent empirical literature, we show how such systems can place disproportionate pressure on early-career researchers by incentivizing safe, tractable and easily evaluated outputs. Structural academic mechanisms such as peer review and funding, escalating publication costs and institutional inequalities interact with precarious employment and hierarchical dependencies. In this environment, we contend that strategic conformity becomes a rational career path. This risks suppressing creativity and critical thinking precisely at the stage when scientific independence could otherwise emerge. Consequently, the probability of substantive contributions by early-career researchers is declining, while talent may increasingly abandon academia or cluster within a limited number of well-resourced institutions and national systems. By adopting a systems-level perspective, we argue that scientific creativity is not merely an individual trait but an emerging property of a supportive academic landscape and that maintaining or restoring it may require substantial structural reforms. These include promoting stable research pathways, decentralized decision-making and evaluation frameworks that better recognize collaboration, originality, persistence and nonlinear career trajectories. Without systemic change, we risk stifling the potential of early-career researchers to go beyond the confines of existing methods and approaches and deliver transformative advances. This would limit their capacity to meaningfully change our understanding of the world or benefit society, with impacts that fall short of their potential.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Phillip J Haubrock, Antonín Kouba, Ismael Soto, Neil Angelo S Abreo, Lorenzo Vilizzi, Dagmara Błońska, Ali Serhan Tarkan, Vanessa De Santis, Ronaldo Sousa, António Barbosa Nogueira, Senne Heeren, Joana Garrido Nogueira, Carlos Cano-Barbacil, Bruno Cremella, Diederik Strubbe, Janine Pereira da Silva, Riccardo Poloni, Pablo Deschepper, Eli S J Thoré, Benjamin Misteli, Jingrui Sun, Martina Panisi, David Dudgeon, Valentini Stamatiadou, Shams M Galib, Chelly Maes, Nompumelelo C Baso, Wouter Beukema, Barbora Števove, Eva Záhorská, Irmak Kurtul, Davinder Kaur, Augusto Frederico Huber, Dariusz Halabowski, Janeide de Assis Guilherme Padilha, Paride Balzani, Cüneyt Kaya, Esra Bayçelebi, Michele Mugnai, Danish A Ahmed, Gülşah Saç, Sadi Aksu, Burak Malik Kaya, Mulkibar Ciftcioglu, Xiaoming Jiang, Marta Rodríguez-Rey, Irene Martín-Forés, Suzana Gonçalves Leles, Lucian Pârvulescu, Jan Pergl, Federica Rossetto, Hui Wei, Natalia I Kirichenko, Elizabeta Briski, Luca Gallitelli, J Robert Britton, Teun Everts. 2026-09-03. How contemporary academic structures constrain scientific creativity and hold back early-career researchers.. https://doi.org/10.1038/s41562-026-02575-5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article